Biogen gains on new Eli Lilly Alzheimer’s data, as beta-amyloid hypothesis ‘lives to see another day’

Failed trial includes some positive results, but analysts and doctors argue about how much.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.